<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kuroda K</submitter><funding>KAKENHI</funding><pagination>4500-4509</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7734156</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>111(12)</volume><pubmed_abstract>Fibroblast growth factor receptor (FGFR) is associated with proliferation, migration, and angiogenesis of carcinomas, and FGFR signaling inhibitors are considered a key drug for the treatment of solid tumors with FGFR overexpression. Amplification of FGFR2 is reportedly identified in 3%-10% of gastric cancers (GCs). The aim of this study is to clarify whether the identification of the circulating tumor cells (CTCs) with FGFR2 overexpression is useful to detect patients with FGFR2-overexpressing GC. One hundred GC patients who underwent gastrectomy were enrolled. A total volume of 8 mL of peripheral blood was collected from each patient just before gastrectomy, and mononuclear cells were enriched by Ficol density gradient centrifugation. These cells were immunostained with PI/CD45/EpCAM/FGF</pubmed_abstract><journal>Cancer science</journal><pubmed_title>Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor.</pubmed_title><pmcid>PMC7734156</pmcid><funding_grant_id>23390329</funding_grant_id><funding_grant_id>18H02883</funding_grant_id><pubmed_authors>Sugimoto A</pubmed_authors><pubmed_authors>Kushiyama S</pubmed_authors><pubmed_authors>Sera T</pubmed_authors><pubmed_authors>Yamamoto Y</pubmed_authors><pubmed_authors>Yashiro M</pubmed_authors><pubmed_authors>Nishimura S</pubmed_authors><pubmed_authors>Okuno T</pubmed_authors><pubmed_authors>Kuroda K</pubmed_authors><pubmed_authors>Miki Y</pubmed_authors><pubmed_authors>Togano S</pubmed_authors><pubmed_authors>Ohira M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor.</name><description>Fibroblast growth factor receptor (FGFR) is associated with proliferation, migration, and angiogenesis of carcinomas, and FGFR signaling inhibitors are considered a key drug for the treatment of solid tumors with FGFR overexpression. Amplification of FGFR2 is reportedly identified in 3%-10% of gastric cancers (GCs). The aim of this study is to clarify whether the identification of the circulating tumor cells (CTCs) with FGFR2 overexpression is useful to detect patients with FGFR2-overexpressing GC. One hundred GC patients who underwent gastrectomy were enrolled. A total volume of 8 mL of peripheral blood was collected from each patient just before gastrectomy, and mononuclear cells were enriched by Ficol density gradient centrifugation. These cells were immunostained with PI/CD45/EpCAM/FGF</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2025-05-31T23:54:05.019Z</modification><creation>2021-02-20T14:29:37Z</creation></dates><accession>S-EPMC7734156</accession><cross_references><pubmed>32946655</pubmed><doi>10.1111/cas.14654</doi></cross_references></HashMap>